Skip to content

Novartis Fellowships

Novartis Institutes for Biomedical Research – Fellowships in Early Clinical Development

The Novartis Institutes for BioMedical Research (NIBR) in conjunction with MCPHS University offers 5 unique post-PharmD Fellowship programs in Early Clinical Drug Development:

  • Biomarker Development (BMD)
  • Clinical Operations – General Medicine
  • Clinical Operations – Translational Clinical Oncology (TCO)
  • Clinical Quality Assurance (QA)
  • Regulatory Affairs (RA)

Each two-year program is designed to provide talented candidates with a high-quality, comprehensive and unique postdoctoral experience. Candidates will gain practical industry experience within the early clinical drug development setting at NIBR. Candidates will also have opportunities to advance their academic skill set as an adjunct faculty member at MCPHS University.

NIBR Overview

The Novartis Institutes for BioMedical Research (NIBR) is the innovation engine of Novartis. We collaborate across scientific and organizational boundaries, with a focus on powerful new technologies that have the potential to help produce therapeutic breakthroughs for patients.

The Novartis global clinical pipeline includes more than 200 projects and over 500 clinical trials. Within NIBR, we have more than 5,600 dedicated scientists and physicians, working across 6 global campuses.

Our Culture

We strive to unleash the power of our people, and we cultivate a company culture that is inspired, curious, and empowered.

Our Values

Our 6 core values underpin our company culture. These values describe the professional behaviors we expect from our employees.

  • Innovation is at the heart of what we do. Associates are encouraged to experiment and take smart risks. Our aim is to foster creative thinking that leads to practical solutions to healthcare and business challenges.
  • Delivering high-quality medicines is critical to our purpose of improving and extending our patients' lives. Our focus on Quality excellence includes continuously enhancing our standards, technology, and training for our people, as well as learning from our mistakes.
  • Collaboration We encourage our associates to put the success of their team first and to value each other's contributions and feedback. We embrace diverse perspectives to develop an inclusive environment where everyone can achieve their full potential.
  • Performance We focus on personal and team achievements by taking smart risks while maintaining high ethical standards.
  • We ask our associates to have the Courage to stand up for their ideas and challenge the status quo, and to do the right thing in the face of resistance or moral dilemmas.
  • Integrity We care about our people, patients, and customers and commit to the highest ethical standards in what we do. We take a principles-based approach to support constructive discussions and improve decision-making.

Fellowship Objectives

The Fellowship is comprised of the NIBR industry component and MCPHS University academic component. Fellows will spend the majority of their time at NIBR obtaining real-world clinical trial experience with a smaller portion of time dedicated to MCPHS University activities. Over the course of the Fellowship, the Fellows will:

  • Develop knowledge of global regulations and guidelines governing clinical research, such as current Good Clinical Practice (cGCP) and International Council on Harmonization (ICH) guidelines
  • Gain practical experience in the drug development process as an integral part of teams working on actual early phase development clinical studies in various phases from start-up through close-out
  • Apply clinical and scientific knowledge to understand the design and conduct of early phase clinical studies
  • Participate in didactic seminars, workshops, and group forums related to clinical research
  • Expand technical writing proficiency of clinical documents such as study protocols and reports
  • Strengthen presentation skills at internal meetings and at national conferences

Please see our brochure for additional details.

For more information, please contact us at